A veterinary clinic which specializes in regenerative medicine reports that demand for cell therapy for animals has been growing. VetStem Biopharma said that since 2002, the clinic has used stem cell therapy on more than 13,000 animals from Canada and the United States.
“I started VetStem 15 years ago because I could see that regenerative medicine was the future and could change the way we practiced,” said Dr. Robert Harman, founder, and CEO of VetStem. “Now, 15 years later VetStem is still leading the way with new approaches to make it easier to treat animals with this cutting edge technology that harnesses our cells own ability to heal”
The California-based clinic was founded mainly to seek for a successful treatment for horses with potentially fatal injuries to tendons and ligaments.
In 2003, VetStem signed a worldwide exclusive license for adipose-derived (fat derived) stem cell technology for veterinary applications. The clinic treated its first horse in September that year.
Two years later, VetStem used regenerative cell therapy on a dog. The clinic also began providing stem cell banking to their clients early in their history so that cells could be stored for future use.
By August of 2005, 500 horses had been treated by VetStem.
Dr. Harman’s team had introduced a new, natural, injectable treatment to the equine and small animal veterinary industry that could serve as an alternative to euthanasia for some conditions.
The U.S. Navy, Office of Naval Research, awarded VetStem a contract to engage in a collaborative study of stem cell biology in marine mammals in 2009. From this, the first peer-reviewed article was published showing the successful isolation of stem cells from dolphin fat.
VetStem also worked with Zoos and Aquariums across the United States to help them treat their residents.
VetStem also had a landmark peer-reviewed manuscript on stem cell therapy of canine osteoarthritis published.
The placebo-controlled study of allogeneic adipose stem cell therapy in dogs with clinical arthritis is the largest study of its kind to date in the veterinary literature.
The final study report was submitted to the FDA and the peer-reviewed manuscript was published in the September 16, 2016 issue of Frontiers in Veterinary Science – Veterinary Regenerative Medicine.
Titled “A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs,” the study evaluated VetStem’s novel allogeneic stem cell product in client-owned dogs in a formal FDA study.
Recently, VetStem announced the initiation of a pivotal field effectiveness and safety study to evaluate the clinical efficacy and safety of its investigational allogeneic adipose stem cell product.
The randomized and blinded placebo-controlled, multi-center study in dogs with clinical osteoarthritis is expected to be completed and submitted to U.S. Food and Drug Administration (FDA) in 2017.
The study is being conducted under an FDA-concurred protocol and is supported by VetStem’s U.S.commercial licensee, Aratana Therapeutics. This pivotal field efficacy study will enroll more than 200 dogs at 17 U.S. veterinary clinics.